(From left) BeiGene’s chief adviser Eric Hedrick, president Wu Xiaobin, founder and CEO John Oyler, co-founder and chairman of scientific advisory board Wang Xiaodong and CFO Howard Liang, attend the BeiGene IPO press conference in Hong Kong on July 29, 2018. Photo: Nora Tam

Hong Kong’s first biotech dual listing runs headlong into a case of bad timing as market slumps

Market observers say the Nasdaq-listed cancer drug maker, which is seeking a dual listing in Hong Kong, has succeeded in selling its IPO by a narrow margin

Topic |   IPO

TOP PICKS

(From left) BeiGene’s chief adviser Eric Hedrick, president Wu Xiaobin, founder and CEO John Oyler, co-founder and chairman of scientific advisory board Wang Xiaodong and CFO Howard Liang, attend the BeiGene IPO press conference in Hong Kong on July 29, 2018. Photo: Nora Tam
READ FULL ARTICLE